Bank of America Forecasts Strong Price Appreciation for Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech (NASDAQ:KRYS) had its price objective raised by investment analysts at Bank of America from $182.00 to $255.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Bank of America‘s target price indicates a potential upside of 34.05% from the stock’s previous close.

KRYS has been the subject of several other research reports. Chardan Capital decreased their price target on shares of Krystal Biotech from $219.00 to $216.00 and set a “buy” rating for the company in a report on Friday, August 22nd. HC Wainwright reissued a “buy” rating and issued a $240.00 price target on shares of Krystal Biotech in a report on Monday, September 15th. Guggenheim set a $224.00 target price on shares of Krystal Biotech and gave the stock a “buy” rating in a research note on Friday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Krystal Biotech in a research note on Wednesday, October 8th. Finally, Citigroup reaffirmed a “neutral” rating and issued a $166.00 target price (down from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $223.00.

Krystal Biotech Stock Up 1.0%

Shares of KRYS stock opened at $190.23 on Friday. Krystal Biotech has a 12-month low of $122.80 and a 12-month high of $207.84. The firm has a market capitalization of $5.51 billion, a price-to-earnings ratio of 38.66 and a beta of 0.64. The firm has a fifty day moving average of $160.70 and a 200-day moving average of $151.29.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The company had revenue of $96.04 million during the quarter, compared to analyst estimates of $95.42 million. Research analysts expect that Krystal Biotech will post 6.14 earnings per share for the current year.

Hedge Funds Weigh In On Krystal Biotech

A number of large investors have recently modified their holdings of the business. Avanza Fonder AB boosted its stake in shares of Krystal Biotech by 50.7% during the 3rd quarter. Avanza Fonder AB now owns 1,418 shares of the company’s stock worth $250,000 after buying an additional 477 shares during the last quarter. Pacer Advisors Inc. boosted its stake in shares of Krystal Biotech by 33.4% during the 3rd quarter. Pacer Advisors Inc. now owns 607 shares of the company’s stock worth $107,000 after buying an additional 152 shares during the last quarter. Exchange Traded Concepts LLC acquired a new position in shares of Krystal Biotech during the 3rd quarter worth about $88,000. AdvisorNet Financial Inc acquired a new position in shares of Krystal Biotech during the 3rd quarter worth about $30,000. Finally, Voya Investment Management LLC boosted its stake in shares of Krystal Biotech by 46.7% during the 3rd quarter. Voya Investment Management LLC now owns 93,908 shares of the company’s stock worth $16,578,000 after buying an additional 29,915 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).